<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-RH8IHI70</identifier><date>2023</date><creator>Trop, Špela</creator><relation>documents/doc/R/URN_NBN_SI_doc-RH8IHI70_001.pdf</relation><relation>documents/doc/R/URN_NBN_SI_doc-RH8IHI70_001.txt</relation><format format_type="issue">3</format><format format_type="volume">74</format><format format_type="type">article</format><format format_type="extent">str. 242</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID">190144515</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-RH8IHI70</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">demenca</subject><subject language_type_id="slv">zdravila</subject><title>FDA Je odobrila prvo zdravilo za zdravljenje vznemirjenosti, povezane z demenco pri Alzheimerjevi bolezni</title></Record>